Employees: 1,310
Size Supriya Lifescience (SUPRIYA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $529M, the 829th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹614.80 on 18 Nov 2026.
Performance Over six months the shares fell 14.7%, against -15.9% for the median peer and +3.8% for the India market (cap-weighted) — 10th highest of 19 in its peer set.
Growth Revenue grew 23.0% over the last twelve months (peer median +6.7%); the operating margin is 26.0% (peer median 6.4%).
Valuation It trades at 36.2× forward earnings against a peer median of 11.3× (most expensive of 8).
Price implies For today's price to make sense, revenue must grow about 28% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.2 points above its cost of capital (14.4% WACC).
Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹8.79B | ₹8.02B | ₹6.80B | ₹5.57B | ₹4.50B |
| Revenue growth | — | +18% | +22% | +24% | — |
| Gross profit | ₹4.47B | ₹3.22B | ₹2.96B | ₹1.97B | ₹1.54B |
| EBITDA | ₹2.63B | ₹2.81B | ₹2.55B | ₹1.69B | ₹1.27B |
| Net income | ₹1.77B | ₹2.09B | ₹1.88B | ₹1.19B | ₹899M |
| Free cash flow | n/a | ₹430M | ₹102M | -₹223M | -₹358M |
| Capital expenditure | n/a | ₹1.52B | ₹1.62B | ₹1.46B | ₹1.08B |
| Total debt | ₹58.0M | ₹54.4M | ₹53.8M | ₹54.9M | ₹225M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SUPRIYA.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -29.6% | -7.0% | 2nd lowest of 20 |
| 6-month return | -14.7% | -15.9% | 10th highest of 19 |
| Distance from 52-week high | -43.3% | -38.7% | 7th lowest of 20 |
| Revenue growth (TTM) | +23.0% | +6.7% | 5th highest of 19 |
| Operating margin | 26.0% | 6.4% | 4th highest of 19 |
| Forward P/E | 36.2× | 11.3× | most expensive of 8 |
| Growth the price implies (Req g, 7 yrs) | 28.2% | -4.9% | 2nd most demanding of 10 |
| Growth delivered (Del g) | +15.8% | +9.6% | 2nd highest of 10 |
| Hurdle (Req g minus delivered) | +12.4 pp | -13.0 pp | 2nd most demanding of 10 |
| ROIC minus cost of capital | +0.2 pp | -2.4 pp | 6th highest of 18 |
| EV / EBITDA | 18.6× | 13.2× | 3rd most expensive of 7 |
| Net debt / EBITDA | -0.3× | 1.5× | 2nd least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Supriya Lifescience SUPRIYA.NS | India | $529M | -15% | +23% | 26% | 36.2× | 28.2% | +15.8% |
| Jinling Pharmaceutical 000919.SZ | China | $529M | -15% | -8% | 1% | n/a | 2.4% | +5.0% |
| Evonile Pharma EVONILE.NS | India | $529M | n/a | -5% | 12% | n/a | 49.3% | -1.5% |
| Electra Therapeutics ETRA | United States | $530M | n/a | n/a | n/a | n/a | n/a | n/a |
| Chimin Health Management 603222.SS | China | $533M | -31% | +1% | -28% | n/a | n/a | n/a |
| Senores Pharmaceuticals SENORES.NS | India | $538M | +3% | +40% | 24% | 32.2× | n/a | n/a |
| Beijing Science Sun Pharmaceutical 300485.SZ | China | $517M | -29% | -11% | -8% | n/a | n/a | n/a |
| Morepen Laboratories MOREPENLAB.NS | India | $542M | +121% | +30% | 11% | n/a | n/a | n/a |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $513M | -22% | -8% | 16% | n/a | -6.1% | +9.6% |
| Egetis Therapeutics EGTX.ST | Sweden | $509M | +76% | +27% | -645% | 15.1× | n/a | n/a |
| Jinhe Biotechnology 002688.SZ | China | $550M | -19% | +7% | 5% | 8.9× | 1.0% | +9.7% |
| Zeria Pharmaceutical 4559.T | Japan | $552M | -12% | +12% | 15% | 9.6× | -12.3% | +11.1% |
| Zevra Therapeutics ZVRA | United States | $552M | -9% | +75% | 31% | 11.3× | -4.9% | +51.6% |
| Indaptus Therapeutics INDP | United States | $505M | +147% | n/a | n/a | n/a | n/a | n/a |
| Boryung 003850.KS | South Korea | $554M | -13% | +6% | 6% | 11.3× | -3.1% | +12.6% |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $505M | +2% | +18% | 39% | n/a | n/a | n/a |
| Aclaris Therapeutics ACRS | United States | $555M | -23% | -59% | -1,412% | n/a | n/a | n/a |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $503M | -17% | +10% | 39% | n/a | -5.4% | +7.6% |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $557M | -24% | -3% | 7% | 9.0× | -5.8% | +4.1% |
| Gyre Therapeutics GYRE | United States | $500M | -28% | +14% | -18% | n/a | n/a | n/a |
| Zhong Zhu Healthcare 600568.SS | China | $562M | -22% | -6% | -34% | n/a | n/a | n/a |